Assertio Q1 net product sales $31.9M; Rolvedon sales grow to $14.5M; guides FY $110-125M

Assertio Holdings, Inc.

2024-Q1 EPS reported -$0.05 revenue$32,448,000

Net product sales of $31.9M in Q1 2024 vs $41.8M in Q1 2023; net loss of $4.5M vs $3.5M loss.
Rolvedon net sales $14.5M, up from $11.0M in Q4 2023, driven by volume growth; same-day dosing trial enrollment completed, data expected year-end.
Indocin net sales $8.7M, down from $10.8M in Q4 2023 due to generic competition.
Adjusted EBITDA (non-GAAP) $7.4M in Q1 2024, up from $4.5M in Q4 2023; SG&A reduced to $18.5M from $24.0M.
FY 2024 guidance reaffirmed: net product sales $110-125M, adjusted EBITDA $20-30M; cash increased to $80.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Assertio Holdings, Inc. updated its three months ended March 31, 2024 guidance (reaffirmed).

Period: three months ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 6, 2024, Assertio Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Assertio Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001808665-24-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.